Planegg

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies

Retrieved on: 
Thursday, February 29, 2024

---  end of press release  ---

Key Points: 
  • Dr. Barbara Lösch, Head of Technology & Innovation, spoke at a Seminar titled “Incorporating Modular Control into Cell Therapies through Receptors to Enhance Therapy Persistence & Safety”.
  • Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene gave a presentation titled “Developing Effective Methods to Monitor, Track & Assess T-Cell Efficacy In Vivo & In Vitro”.
  • “With our E2E Platform, we provide solutions for all of these key areas, with innovation at multiple sequential steps of the discovery and development process.
  • With our unique set of technologies, we are well positioned to provide new, best-in-class differentiated TCR-T therapies for treatment of patients with solid tumors.”

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Retrieved on: 
Monday, February 12, 2024

MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB

Key Points: 
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB
    Planegg/Martinsried, February 12, 2024.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015.
  • Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.
  • “The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial.

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Retrieved on: 
Wednesday, September 27, 2023

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology.
  • Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.
  • “We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform.
  • This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho, CEO at Medigene AG.

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

Retrieved on: 
Monday, September 18, 2023

“The selection of this first mKRAS (mutant KRAS) lead TCR further validates our capabilities to generate 3S TCRs across both neoantigens and cancer-testis antigens.

Key Points: 
  • “The selection of this first mKRAS (mutant KRAS) lead TCR further validates our capabilities to generate 3S TCRs across both neoantigens and cancer-testis antigens.
  • One such attribute is the identification of a TCR candidate demonstrating bi-specific recognition for both the KRAS G12V and G12C mutations.
  • Directed TCR discovery efforts in the future will enable identification of an optimal KRAS G12C-specific TCR lead.
  • Global incidence of solid tumors expressing KRAS mutations is estimated to be in excess of 300,000 patients.

Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 17, 2023

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial and operational results for the six months ended June 30, 2023.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial and operational results for the six months ended June 30, 2023.
  • “In the first half of 2023, we have accomplished many significant milestones, and made substantial progress towards our strategic objectives”, said Selwyn Ho, Chief Executive Officer at Medigene.
  • “We advanced our IND / CTA enabling work on MDG1015 and expanded our pipeline into neoantigens targeting multiple KRAS mutations and HLAs in solid tumors.
  • The Executive Management Board, therefore, maintains its guidance for the fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.

Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

Retrieved on: 
Wednesday, August 16, 2023

---  end of press release  ---

Key Points: 
  • Planegg/Martinsried, August 16, 2023.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023.
  • Members of Medigene's management team will participate in a fireside chat and will be available for virtual one-on-one meetings with registered investors.

Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs

Retrieved on: 
Thursday, June 1, 2023

Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet need

Key Points: 
  • Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet need
    Management to host an R&D Event to discuss pipeline expansion and evolution of the end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET
    Planegg/Martinsried, June 1, 2023.
  • KRAS mutations are widely recognized as the most common oncogene mutations in difficult-to-treat solid tumors existing in ~30% of solid tumors, such as pancreatic, colorectal, endometrial and non-small-cell lung cancer.
  • Global incidence of solid tumors expressing KRAS mutations is estimated to be in excess of 300,000 patients.
  • “Our pipeline expansion into neoantigens with multiple KRAS targets represents a major advance in our pursuit to develop best-in-class TCR-T therapies for patients suffering from difficult-to-treat solid tumors,” said Dr. Selwyn Ho, Chief Executive Officer at Medigene.

DGAP-News: MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

Retrieved on: 
Tuesday, January 12, 2021

PLANEGG/MUNICH, Germany and MONTREAL, Canada - January 12, 2021 - MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ: INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.

Key Points: 
  • PLANEGG/MUNICH, Germany and MONTREAL, Canada - January 12, 2021 - MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ: INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.
  • Incyte has exclusive commercialization rights for tafasitamab outside of the United States and, if approved, Incyte will hold the marketing authorization for tafasitamab in Canada.
  • This NDS marks the second marketing application that Incyte Biosciences Canada has made to Health Canada since establishing operations in Canada in April 2020.
  • In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally.

DGAP-News: 4SC provides Q1 2020 update

Retrieved on: 
Tuesday, April 21, 2020

Planegg-Martinsried, Germany, 21 April 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2020, presenting all material developments up to 31 March 2020 and the Company's current outlook.

Key Points: 
  • Planegg-Martinsried, Germany, 21 April 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2020, presenting all material developments up to 31 March 2020 and the Company's current outlook.
  • As of 31 March 2020, 4SC holds cash balance/funds of 40.350 million as compared to 45.765 million as of 31 December 2019.
  • The monthly use of cash from operations amounted to 1.677 million on average in the first quarter of 2020 (Q1 2019: 1.263 million) and was below the range of 2.2 million and 2.6 million forecast for 2020.
  • The Management Board of 4SC believes that the funds should be sufficient to finance 4SC into the second half of 2021.

DGAP-News: 4SC AG provides results for financial year 2019 and outlook

Retrieved on: 
Wednesday, March 25, 2020

Planegg-Martinsried, Germany, 25 March 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2019, presenting all material reporting period developments and provides an outlook for 2020.

Key Points: 
  • Planegg-Martinsried, Germany, 25 March 2020 - 4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2019, presenting all material reporting period developments and provides an outlook for 2020.
  • As of 31 December 2019, 4SC holds cash balance/funds of 45,765 thousand (31 December 2018: 25,036 thousand).
  • For 2020, 4SC is expecting an average monthly use of cash from operations of between 2,200 thousand and 2,600 thousand.
  • 4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs.